Bayer grows sales and earnings significantly

Group sales rise by 14.3 percent (Fx & portfolio adj.) to 9.781 billion euros / EBITDA before special items increases by 16.4 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent to 1.05 euros / Net income at 85 million euros / Free cash flow remains strong at 1.954 billion euros / Revised outlook confirms good business performance

Address by Werner Baumann and Wolfgang Nickl

Chairman of the Board of Management / Chief Financial Officer

On-demand recording of the conference call with the speech given by Werner Baumann and Wolfgang Nickl, and the subsequent Q&A session